Veracyte
Updated NCCN Guidelines Adjust Ratings for Prostate Cancer Genetic Tests
The newest version ups its endorsement of somatic genomic testing to "recommended" for advanced cancers and shifts its recommendations on early-stage risk assays.
Wolfe Research Initiates Coverage of Grail With Peer Perform, Veracyte With Outperform Rating
Grail's flagship product, Galleri, detects more than 50 types of cancer, while Veracyte offers tests intended to personalize treatment for thyroid, breast, and lung cancer.
As the company explores new testing areas and technologies, the prostate cancer prognostic has become an important backbone.
UBS Initiates Coverage of Veracyte With Buy Rating
Analysts noted that they envision "durable growth" in Veracyte's Afirma and Decipher Prostate tests and "long-term growth potential" from its MRD testing business.
Local Coverage Determinations Roundup: Veracyte, Sonic Healthcare USA
A roundup of local coverage determinations from Medicare administrative contractors.
Sep 3, 2024
360Dx Top 30 Ticks up 2 Percent in August
Aug 8, 2024
Local Coverage Determinations Roundup: Veracyte
Apr 3, 2023